SOLICITATION NOTICE
R -- Haemophilus influenzae among southwestern American Indian children
- Notice Date
- 7/18/2018
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 75D30118R67930
- Archive Date
- 8/17/2018
- Point of Contact
- Liubov A. Kriel, Phone: 7704882856
- E-Mail Address
-
vyh1@cdc.gov
(vyh1@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Center for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) intends to award a sole source contract to Center for American Indian Health Johns Hopkins Bloomberg School of Public Health, 415 N. Washington St., Baltimore, MD 21231 for the acquisition of the effort entitled "Haemophilus influenzae among southwestern American Indian children". The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is NAICS 541990 - Other Professional, Scientific, and Technical Services. Historically, American Indian and Alaska Native (AI/AN) children aged <5 years have suffered from invasive H. influenzae type b (Hib) disease at rates at least 5 times higher than the general U.S. population. Following introduction of a primary series and booster dose with conjugate Hib vaccine in the late 1980s, rates of Hib disease decreased substantially among both AI/AN and non-Native children. However, rates of Hib disease among AI/AN children remain much higher than among non-AI/AN children, despite Hib vaccine coverage similar to or greater than the national average and proven efficacy of Hib vaccine in this population. Additionally, AI/AN children aged <5 years have a higher incidence of all forms of invasive H. influenzae disease than children in all other races. Despite comprising <3% of the general population, it is estimated that 10% of the burden of invasive H. influenzae disease in the US occurs in AI/AN individuals, reflecting a serious health disparity in a life-threatening illness. In recent years, active Hib surveillance conducted by the Johns Hopkins School of Public Health Center for American Indian Health (CAIH) has identified a shift in Hib disease among Navajo children <5 years: while Hib disease historically peaked in infants 4-6 months of age, two-thirds of cases in the past 3 years have occurred in children aged 1-5 years who have received ≥2 doses of Hib vaccine. Most recently, CAIH has noted a concerning increase in Hib disease among Navajo children <5 years. Additionally, invasive disease caused by H. influenzae serotype a (Hia) has increased in recent years in the United States. While rates of Hia are increasing among all children in the U.S., Navajo children have a substantially greater incidence; among Navajo children <5 years of age in 2004-2016, the average annual rate was 16.7 cases/100,000 population. This is compared to an incidence of Hia disease in children <5 years of age from 2002-2014 at 0.43 per 100,000 in the general U.S. population. These epidemiologic changes and increase in disease among the Navajo may be due to a persistent reservoir of Hib carriage in the community, waning immunity following vaccination, or other unrecognized risk factors. Hib vaccination induces serum antibody production (anti-PRP) and reduces the nasopharyngeal carriage prevalence of H. influenzae type b, thereby diminishing the risk of invasive disease. Reductions in carriage also reduce transmission of Hib between individuals. Numerous studies have documented declines in Hib carriage following vaccination, although this effect appears to wane with increasing time since last vaccination. In settings where resurgent Hib disease has been detected, a reservoir of carriage has been identified in school-aged children. In the pre-Hib vaccine era, invasive Hib disease occurred at a younger age in AI/AN children compared to general U.S. children. To provide early protection, the PRP-OMP Hib vaccine, which elicits protective antibody concentrations after one dose, was preferentially recommended for the primary series in AI/AN children. However, the peak (post-booster) antibody concentration is lower for PRP-OMP compared to other Hib vaccines. Waning immunity following the booster dose may result in susceptibility to infection, especially if exposure to Hib via oropharyngeal colonization in the community is ongoing. Knowledge of disease burden and Hia carriage in this at-risk population could impact future policy decisions regarding any other potential new vaccines. The purpose of this project is to (1) determine whether a reservoir for Hia and Hib transmission exists among AI children by assessing oropharyngeal carriage of H. influenzae; (2) determine if waning immunity to Hib vaccination may be contributing to invasive H. influenzae disease by assessing sero-prevalence of anti-PRP antibodies; and (3) assess current risk factors for invasive Hia and Hib disease among AI children by conducting a case-control study. The Center for American Indian Health (CAIH) is an independent center within the Johns Hopkins School of Public Health with satellite offices on tribal lands of the White Mountain, Navajo Nation and Santo Domingo pueblo. CAIH has a history of over 35 years of collaboration with Southwestern tribes; their current programs reach more than 100 tribal communities in 16 states. They currently operate 10 field offices in 4 tribal communities, employing staff from the American Indian (AI) community, and supporting the development, implementation and evaluation of public health activities to improve the health of AI communities. They are a trusted community partner and have relationships with the Indian Health Service, tribal leadership and community-based organizations. There is no other known to CDC group with comparable surveillance or research infrastructure established among this target population. This type of proposed investigation can only be carried out by CAIH due to existing programs, support and research capability. Therefore, this company is uniquely positioned to performing this study. Thus, the Center for American Indian Health (CAIH), is the only company that can be used. As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to the Center for American Indian Health (CAIH). However, firms that believe they can meet these requirements are encouraged to identify themselves and give written notice by providing a capability statement to the Contracting Officer by August 2, 2018. The Contracting Officer will not respond to verbal request. All requests must be in writing. A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Inquiries shall be sent to Liubov Kriel by email at vyh1@cdc.gov and reference solicitation number 75D30118-R-67930 on the subject line.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/75D30118R67930/listing.html)
- Place of Performance
- Address: Baltimore, Maryland, 21231, United States
- Zip Code: 21231
- Zip Code: 21231
- Record
- SN04996968-W 20180720/180718231007-1f6bbd1533fdd3958cdfbfba1b1a8dfe (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |